FRATTAROLI JOSEPH 4
4 · Inhibikase Therapeutics, Inc. · Filed Mar 21, 2022
Insider Transaction Report
Form 4
FRATTAROLI JOSEPH
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-03-07+62,500→ 62,500 totalExercise: $1.07Exp: 2029-03-07→ Common Stock (62,500 underlying)
Holdings
- 44,143(indirect: By Flagship Consulting, Inc.)
Common Stock
Footnotes (2)
- [F1]One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2023, subject to continued employment through each such vesting date.
- [F2]The original Form 4, filed on March 9, 2022, is being amended by this Form 4 amendment to correct an error that misreported that the 24 equal monthly installments mentioned in footnote 1 would begin on the first day of April 2024, rather than the first day of April 2023 as intended.